Arcus Biosciences Stock Quote RCUS - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

15.55

Bid

Ask

Volume

505,353

14.59 Day's Range 15.615

12.95 52 Week Range 25.47

Market Cap

1.413B

Previous Close

14.73

Open

14.73

Last Trade

147498

15.55

Last Trade Time

Financial Volume

$ 7,726,094

VWAP

15.2885

Average Volume (3m)

787,633

Shares Outstanding

90,864,829

Dividend Yield

PE Ratio

-4.60

Earnings Per Share (EPS)

-3.38

Revenue

117M

Net Profit

-307M

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.arcusbio.com

Headquarters

Camden, Delaware, USA

Founded

1970

Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $14.73. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 12.95 to $ 25.47.

Arcus Biosciences currently has 90,864,829 shares outstanding. The market capitalization of Arcus Biosciences is $1.41 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.60.

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.78	5.28097494922	14.77	15.85	14.1	524368	15.00048873	CS
4	-3.23	-17.1991480298	18.78	18.85	14.1	538998	16.26974216	CS
12	0	0	15.55	20.31	14.1	787633	17.46167272	CS
26	-0.11	-0.702426564496	15.66	20.31	12.95	800319	16.81761226	CS
52	-2.87	-15.5808903366	18.42	25.47	12.95	870023	18.3530528	CS
156	-20.33	-56.6610925307	35.88	49.1	12.95	851523	24.45568102	CS
260	4.81	44.7858472998	10.74	49.1	6.3	681702	24.23631598	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M